Earningsreport

Q3/2024 9/30/2024 EPS -0.720 ZacksConsensus -0.650 ActVsEst (0.070) - Miss

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com